Carol Walton, PhD
Carol has a unique knowledge of the development and commercialisation of cell therapy. Her expertise includes understanding the influences of key stakeholders (including: regulators, clinicians and healthcare insurers) on the development of cell-based therapies. Carol is widely networked and has conducted numerous cell therapy development case studies with key opinion leaders from industry, FDA, EMA and the Centers for Medicare & Medicaid Services. She has published a number of scientific papers and reports as well as a book chapter related to the commercialisation of cell-based therapies. She has also been highly instrumental in establishing The Regenerative Medicine Coalition. Carol was born and raised in Andorra. She graduated with a Bachelor’s and a Master’s degree in Bioengineering specialising in Biotechnology from the University of Brussels in 2008. She completed her Master’s thesis at the University of Oxford in Molecular Biology. Carol has also studied at the Universitat Autònoma de Barcelona in Spanish and Catalan for her Bioengineering degree in 2006-2007. Subsequently, in 2008-2009, Carol completed an M.Phil in Bioscience Enterprise at the University of Cambridge in affiliation with the Massachusetts Institute of Technology. Currently, she is a final year Doctoral Researcher working on the development and commercialisation of cell therapy at the University of Cambridge under the supervision of Dr. Paul Heffernan from the Institute for Manufacturing and Prof. Chris Lowe, Director of the Institute of Biotechnology.